Endoscopy is, currently, the initial investigation ofchoice for the investigation ofgastroesophageal reflux disease (GERD) in clinical practice and clinical research. Erosion severity is predictive ofa patient's response to therapy and of the likelihood of relapse after therapy. It is, therefore, important to grade the severity of erosive reflux esophagitis, particularly in the context of clinical trials.
Endoscopy is not universally applicable: 40 to 60 percent ofpatients with typical reflux symptoms do not have esophageal erosions and are now considered to have "endoscopy negative reflux disease" (ENRD). Thus, endoscopy is not thefinal arbiter as to a diagnosis of reflux disease, and it is not, therefore, a necessary prerequisite to therapy. Endoscopy is indicated atfirst presentation for patients with alarm symptoms referable to the upper gastrointestinal tract. It has also been proposed that all patients with chronic GERD should have a "once-in-a-lifetime" endoscopy; in the absence of Barrett's esophagus or other complications, no follow-up is required unless the patient's symptoms change significantly. A surveillance program with multiple biopsies should be instituted ifthere is evidence ofBarrett's esophagus. Endoscopic evaluation should document the presence and extent of esophageal erosions using the L.A. or MUSE classification systems; complications should also be documented and may be recorded using the MUSE classification. Non-erosive changes such as erythema may be ignored on the basis ofpresent evidence, and there are no clear data to support the use of endoscopic biopsies for the diagnosis of GERD.
a To whom all correspondence should be addressed: David Armstrong, Division of Gastroenterology, Room [2, 3] and "balloon" cells [4] have all been described in association with gastroesophageal reflux disease, the sensitivity, and specificity of these findings for the diagnosis of GERD have not been defined, and the role of histology, therefore, remains undefined.
In general, the complications of GERD are relatively infrequent, and the most frequent identifiable lesion remains the esophageal erosion or "touche peptique" described by Savary [5] . For patients with erosive esophagitis, the recurrence of symptoms after therapy correlates well with the recurrence of esophageal erosions ( Figure 1 ) [6] . Neither the extent nor the severity of erosions correlates directly with symptom severity in an individual patient; however, erosion severity is predictive of a patient's probable response to therapy and also of the likelihood of relapse after cessation of therapy, unlike the presence of minor, non-erosive changes [7, 8] . It is, therefore, important to grade the severity of erosive reflux esophagitis, particularly in the context of clinical trials.
ENDOSCOPIC GRADING OF ESOPHAGITIS SEVERITY
The most widely used classification system is that described first by Savary & Miller, in which disease severity is graded according to the extent of esophageal erosions [9] . The Savary-Miller classification recognizes also that complications of GERD are important but, in both versions described by the authors [9, 10] 2 ). This classification provides clear definitions of the different endoscopic features of GERD and is based on a pictorial report form, which allows the endoscopist to make a clear record of esophagitis severity [11, 12] .
In recent years, it has become clear that the profusion of classification systems has made it increasingly difficult to compare the results of different therapeutic trials in GERD. This prompted the formation of an International Working Group charged with developing a standardized endoscopic esophagitis classification system, which would be generally acceptable in clinical or research practice. In an initial step, the group identified endoscopic Figure 3 ). This study suggested also that experienced endoscopists could identify reliably, some of the minor changes (erythema, edema, friability) attributable to reflux [13] . [14, 15] . For some physicians, this represents proof final that these patients do not have GERD and, in some jurisdictions, that these patients do not merit therapy with proton pump inhibitors. Despite this, many such patients will have evidence of a temporal correlation between reflux episodes and symptoms during esophageal pH monitoring studies, and their symptoms will often be relieved by medical anti-reflux therapy [14, 15] . Thus, it is becoming clear that the clinical spectrum of GERD does include ENRD and that endoscopy is not, therefore, the final arbiter as to a diagnosis of reflux disease.
ROLE OF ENDOSCOPY FOR EVALUATION OF GERD
What then is the place of endoscopy in clinical practice? Endoscopic confirmation of esophageal erosions is highly specific for a diagnosis of GERD, but it has low sensitivity, and there is, therefore, the danger that endoscopy alone will underestimate greatly the prevalence of GERD.
An outcomes study has shown [16] that endoscopy leads to a significant change in therapy for patients with reflux symptoms, but the change was most marked in patients who had erosive esophagitis; it is not clear that the failure to alter therapy in patients with ENRD was appropriate. It has been argued that endoscopy is not necessary to make a diagnosis of GERD in a patient with typical symptoms unless there is a suspicion of serious underlying disease based on the patient's age or alarm symptoms such as weight loss, dysphagia, anemia or gastrointestinal blood loss. If reimbursement policies mandate a confirmed diagnosis of erosive esophagitis before effective antisecretory therapy can be started, endoscopy should be performed early, and, if possible, the patient should stop acid antisecretory or prokinetic therapy at least one to two weeks prior to endoscopy. If erosive esophagitis is confirmed, there seems to be no reason to repeat endoscopy simply to confirm healing since there is a good correlation between symptoms and the recurrence of erosions [6] . In the majority of patients, GERD is a chronic, relapsing condition, and the only indication for repeat endoscopy would be a significant change or worsening of the patient's symptoms.
For the present, the other major indication for endoscopy is the exclusion of Barrett's esophagus. There is continuing controversy over the advisability of surveillance follow-up for patients with Barrett's esophagus, but a cost-modeling study suggests that it is cost-effective, if the incidence of carcinoma in Barrett's exceeds 1 percent [17] ; this provides support for current recommendations that endoscopic surveillance be conducted every two years in patients with confirmed Barrett's esophagus. The natural history of Barrett's esophagus is still unclear but data from Olmsted County [18] 
